Alogliptin vs Saxagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Alogliptin · Nesina
Marketed by Takeda Pharmaceutical Company and partners
NCT00286429 · Phase 3 · completed
The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.
Next expected readout: December 2026 · NCT07093476 (registry estimate)
Reported efficacy
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)
Result source: NCT02856113
Saxagliptin · Onglyza
Rights held by AstraZeneca and partners; US product discontinued
NCT00121667 · Phase 3 · completed
Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.
Next expected readout: February 2027 · NCT02969798 (registry estimate)
Reported efficacy
Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)
Result source: NCT00121667
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Alogliptin | Saxagliptin |
|---|---|---|
| HbA1c, change | -0.7% vs -0.1%−0.6 vs placeboNCT00286429285 other results
| -0.7% vs -0.3%−0.4 vs placeboNCT0075758819 other results
|
| Body weight, change (kg) | 0.6 vs 0.6±0 vs placeboNCT00286429111 other results
| -1.9 vs -0.4−1.5 vs placeboNCT016463207 other results
|
| HbA1c below 7% | 63.3% vs 30%+33.3 vs placeboNCT012891192 other results
| 44.4% vs 16.6%+27.8 vs placeboNCT0012166715 other results
|
| Fasting plasma glucose, change | -0.7 vs 0.3−1 vs placeboNCT00286429351 other results
| -0.6 vs -0.3−0.2 vs placeboNCT0075758811 other results
|
| 3-point MACE (% with event) | 11.3% vs 11.8%−0.5 vs placeboNCT00968708 | 7.4% vs 7.4%±0 vs placeboNCT01107886 |
HbA1c, change
- Alogliptin
- -0.7% vs -0.1%−0.6 vs placeboNCT00286429
285 other results
- -0.6% vs -0.0% NCT00286455
- 0.1% vs -0.0% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.1% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.6% vs -0.1% NCT00286429
- -0.6% vs -0.0% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.6% vs -0.1% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.6% vs 0.1% NCT01023581
- -1.3% vs -0.1% NCT00328627
- -1.4% vs -0.1% NCT00328627
- -1.6% vs -0.1% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -1.0% vs -1.1% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -0.9% vs -0.4% NCT00432276
- -1.0% vs 0.0% NCT01263483
- -1.7% vs -1.1% NCT00395512
- -0.7% vs -0.6% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.7% vs 0.3% NCT01318083
- -1.0% vs -0.2% NCT01318070
- -0.9% vs 0.0% NCT01263483
- -1.6% vs -1.1% NCT00395512
- -0.7% vs -0.6% NCT00856284
- -0.6% vs 0.3% NCT01318083
- -0.9% vs -0.2% NCT01318070
- 0.3% vs 0.8% NCT02856113
- 0.1% vs 0.5% NCT02856113
- -0.7% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -1.0% vs -0.2% NCT00328627
- -0.8% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.2% vs -0.2% NCT02856113
- -0.8% vs -0.2% NCT00286429
- -0.7% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -1.0% vs -0.3% NCT00328627
- -0.8% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.7% vs -0.1% NCT00286455
- -0.4% vs -0.3% NCT02856113
- -0.5% vs 0.1% NCT01023581
- -0.9% vs -0.3% NCT00328627
- -0.8% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.5% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.6% vs -0.3% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.3% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.5% vs -0.1% NCT00286494
- -0.4% vs -0.1% NCT00286442
- -0.8% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.2% NCT00328627
- -0.7% vs -0.3% NCT00286494
- -0.6% vs -0.1% NCT00286442
- -0.8% vs -0.2% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.3% NCT00286494
- -0.7% vs -0.1% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.6% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.7% vs -0.2% NCT00286494
- -0.7% vs -0.2% NCT00286442
- -0.8% vs -0.3% NCT00286429
- -0.5% vs -0.1% NCT00286455
- -0.6% vs 0.1% NCT01023581
- -0.8% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00286494
- -0.6% vs -0.2% NCT00286442
- -0.5% vs -0.3% NCT00286429
- -0.4% vs -0.1% NCT00286455
- -0.4% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.4% vs -0.1% NCT00286494
- -0.4% vs -0.1% NCT00286442
- -1.4% vs -0.2% NCT00328627
- -1.5% vs -0.2% NCT00328627
- -1.7% vs -0.2% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.7% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.0% vs -0.3% NCT00328627
- -1.2% vs -0.3% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -1.4% vs -0.2% NCT00328627
- -1.4% vs -0.2% NCT00328627
- -1.6% vs -0.2% NCT00328627
- -1.3% vs 0.1% NCT01023581
- -1.5% vs 0.1% NCT01023581
- -1.4% vs -0.3% NCT00328627
- -1.4% vs -0.3% NCT00328627
- -1.5% vs -0.3% NCT00328627
- -1.2% vs 0.1% NCT01023581
- -1.4% vs 0.1% NCT01023581
- -1.2% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.3% vs -0.3% NCT00328627
- -1.1% vs 0.1% NCT01023581
- -1.2% vs 0.1% NCT01023581
- -1.0% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -1.1% vs -0.3% NCT00328627
- -0.7% vs 0.1% NCT01023581
- -0.8% vs 0.1% NCT01023581
- -0.5% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -0.6% vs -0.2% NCT00328627
- -1.0% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.8% vs -0.4% NCT01289119
- -0.9% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.7% vs -0.4% NCT01289119
- -0.6% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -0.4% vs -0.2% NCT01289119
- -1% vs -1.2% NCT00395512
- -1.0% vs -1.2% NCT00395512
- -1.0% vs -1.0% NCT00395512
- -0.8% vs -0.7% NCT00395512
- -0.6% vs -0.3% NCT00395512
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.4% NCT00432276
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.9% vs -0.5% NCT00432276
- -0.7% vs -0.0% NCT01263483
- -0.4% vs -0.0% NCT01263483
- -0.2% vs -0.0% NCT01263483
- -1.7% vs -1.2% NCT00395512
- -0.8% vs -0.8% NCT00856284
- -0.9% vs -0.4% NCT00432276
- -1.7% vs -1.2% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.8% vs -0.3% NCT00432276
- -1.6% vs -1.0% NCT00395512
- -0.6% vs -0.7% NCT00856284
- -0.7% vs -0.3% NCT00432276
- -1.2% vs -0.7% NCT00395512
- -0.4% vs -0.4% NCT00856284
- -0.6% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.4% vs -0.1% NCT00432276
- -0.8% vs -0.0% NCT01263483
- -0.6% vs -0.3% NCT00395512
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.8% vs -0.8% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.8% vs -0.7% NCT00856284
- -0.7% vs -0.8% NCT00856284
- -0.6% vs -0.7% NCT00856284
- -0.4% vs -0.4% NCT00856284
- -0.4% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.4% vs -0.0% NCT01263483
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.2% vs -0.0% NCT01263483
- -1.5% vs -1.2% NCT00395512
- -1.4% vs -1.2% NCT00395512
- -1.3% vs -1.0% NCT00395512
- -1.0% vs -0.7% NCT00395512
- -0.5% vs 0.2% NCT01318083
- -0.8% vs -0.2% NCT01318070
- -0.5% vs -0.3% NCT00395512
- -0.3% vs 0.1% NCT01318083
- -0.5% vs -0.1% NCT01318070
- -0.1% vs 0.1% NCT01318083
- -0.2% vs -0.0% NCT01318070
- -0.6% vs -0.0% NCT00755846
- -0.8% vs 0.1% NCT01263470
- -0.5% vs -0.0% NCT00755846
- -0.7% vs 0.1% NCT01263470
- -0.5% vs -0.0% NCT00755846
- -0.4% vs -0.0% NCT00755846
- -0.8% vs 0.1% NCT01263470
- -0.2% vs -0.0% NCT00755846
- -0.5% vs 0.1% NCT01263470
- -0.7% vs 0% NCT01263470
- -0.4% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.6% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.7% vs 0% NCT01263470
- -0.3% vs 0.0% NCT00755846
- -0.4% vs -0.0% NCT01263470
- -0.1% vs 0% NCT01263470
- -0.5% vs 0% NCT01263470
- -0.1% vs 0.0% NCT00755846
- -0.3% vs -0.0% NCT01263470
- -0.2% vs 0% NCT01263470
- -0.7% vs -0.4% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.7% vs -0.1% NCT01263496
- -0.6% vs -0.2% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.7% vs -0.4% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.7% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.7% vs -0.1% NCT01263496
- -0.5% vs -0.2% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.8% vs -0.4% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.8% vs -0.3% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.9% vs -0.3% NCT01263496
- -0.9% vs -0.1% NCT01263496
- -0.9% vs -0.2% NCT01263496
- -0.5% vs -0.4% NCT01263496
- -0.4% vs -0.4% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.3% vs -0.3% NCT01263496
- -0.4% vs -0.3% NCT01263496
- -0.5% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.3% NCT01263496
- -0.6% vs -0.1% NCT01263496
- -0.4% vs -0.2% NCT01263496
- Saxagliptin
- -0.7% vs -0.3%−0.4 vs placeboNCT00757588
19 other results
- 7.1% vs 7.5% NCT00661362
- -0.5% vs -0.2% NCT01619059
- 0.1% vs 0.5% NCT03199053
- -0.8% vs -0.1% NCT01646320
- -0.7% vs -0.1% NCT01128153
- -0.7% vs 0.6% NCT01204775
- -1% vs 0.9% NCT01434186
- -1.4% vs -1.0% NCT02419612
- -1.4% vs -1.1% NCT02284893
- -1.7% vs -1.5% NCT02551874
- -1.0% vs -0.7% NCT02681094
- -0.2% vs -0.7% NCT03199053
- 0.1% vs -0.7% NCT03199053
- -0.8% vs -1.0% NCT02471404
- -1.2% vs -1.0% NCT02471404
- -0.8% vs -0.8% NCT02243176
- -0.8% vs -0.8% NCT02243176
- -0.5% vs -0.4% NCT01006590
- -0.4% vs -0.6% NCT01006603
Body weight, change (kg)
- Alogliptin
- 0.6 vs 0.6±0 vs placeboNCT00286429
111 other results
- -0.2 vs 0.2 NCT00286455
- -0.7 vs -0.7 NCT00328627
- 1.1 vs 1.0 NCT00286494
- -0.7 vs -0.4 NCT00286442
- 0.7 vs -0.2 NCT00286468
- 0.5 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.5 vs -0.6 NCT00328627
- 0.9 vs 0.9 NCT00286494
- -0.6 vs -0.4 NCT00286442
- 0.6 vs -0.3 NCT00286468
- 0.3 vs 0.5 NCT00286429
- 0.1 vs -0.3 NCT00286455
- -0.6 vs -0.5 NCT00328627
- 0.6 vs 0.6 NCT00286494
- -0.6 vs -0.6 NCT00286442
- 0.4 vs -0.1 NCT00286468
- 0.2 vs 0.4 NCT00286429
- -0.0 vs -0.4 NCT00286455
- -0.5 vs -0.1 NCT00328627
- 0.4 vs 0.4 NCT00286494
- -0.5 vs -0.1 NCT00286442
- 0.3 vs -0.3 NCT00286468
- 0.7 vs 0.6 NCT00286429
- -0.1 vs 0.2 NCT00286455
- -0.0 vs -0.7 NCT00328627
- 1.5 vs 1.0 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.6 vs -0.2 NCT00286468
- 0.6 vs 0.7 NCT00286429
- -0.2 vs -0.2 NCT00286455
- -0.1 vs -0.6 NCT00328627
- 1.1 vs 0.9 NCT00286494
- -0.4 vs -0.4 NCT00286442
- 0.8 vs -0.3 NCT00286468
- 0.4 vs 0.5 NCT00286429
- -0.4 vs -0.3 NCT00286455
- -0.1 vs -0.5 NCT00328627
- 0.7 vs 0.6 NCT00286494
- -0.3 vs -0.6 NCT00286442
- 0.6 vs -0.1 NCT00286468
- 0.1 vs 0.4 NCT00286429
- 0.0 vs -0.4 NCT00286455
- -0.1 vs -0.1 NCT00328627
- 0.5 vs 0.4 NCT00286494
- -0.3 vs -0.1 NCT00286442
- 0.5 vs -0.3 NCT00286468
- 1.3 vs -0.7 NCT00328627
- 2.1 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 0.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 1.8 vs -0.6 NCT00328627
- 0.4 vs -0.5 NCT00328627
- 1.0 vs -0.5 NCT00328627
- 1.1 vs -0.5 NCT00328627
- 0.2 vs -0.1 NCT00328627
- 0.7 vs -0.1 NCT00328627
- 0.9 vs -0.1 NCT00328627
- 1.3 vs -0.7 NCT00328627
- 1.9 vs -0.7 NCT00328627
- 2.3 vs -0.7 NCT00328627
- 1.0 vs -0.6 NCT00328627
- 1.4 vs -0.6 NCT00328627
- 1.9 vs -0.6 NCT00328627
- 0.2 vs -0.5 NCT00328627
- 0.6 vs -0.5 NCT00328627
- 0.9 vs -0.5 NCT00328627
- 0.1 vs -0.1 NCT00328627
- 0.5 vs -0.1 NCT00328627
- 0.4 vs -0.1 NCT00328627
- -0.9 vs -1.6 NCT01289119
- -0.8 vs -1.6 NCT01289119
- -0.1 vs -1.6 NCT01289119
- -0.7 vs -1.0 NCT01289119
- -0.4 vs -1.0 NCT01289119
- -0.1 vs -1.0 NCT01289119
- -0.9 vs 0.9 NCT00856284
- 1.1 vs 1.6 NCT00432276
- 1.1 vs 1.5 NCT00432276
- -0.9 vs 1.0 NCT00856284
- -0.9 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.9 vs 0.9 NCT00856284
- 0.7 vs 1.0 NCT00432276
- -0.9 vs 0.9 NCT00856284
- -0.5 vs 0.7 NCT00856284
- 0.3 vs 0.6 NCT00432276
- 0.3 vs 0.5 NCT00432276
- 0.2 vs 0.3 NCT00432276
- -0.9 vs 0.9 NCT00856284
- -0.6 vs 0.9 NCT00856284
- -0.6 vs 1.0 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.8 vs 0.9 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.5 vs 0.7 NCT00856284
- -0.7 vs 0.9 NCT00856284
- -0.3 vs 2.2 NCT00395512
- -0.5 vs 1.6 NCT00395512
- -0.8 vs 1.0 NCT00395512
- -0.3 vs 0.6 NCT00395512
- 3.1 vs 2.2 NCT00395512
- 2.4 vs 1.6 NCT00395512
- 1.4 vs 1.0 NCT00395512
- 0.8 vs 0.6 NCT00395512
- 2.5 vs 2.2 NCT00395512
- 1.9 vs 1.6 NCT00395512
- 1.2 vs 1.0 NCT00395512
- 0.7 vs 0.6 NCT00395512
- Saxagliptin
- -1.9 vs -0.4−1.5 vs placeboNCT01646320
7 other results
- -3.1 vs 0.9 NCT02419612
- -1.9 vs -0.5 NCT02284893
- -1.5 vs 2.1 NCT02551874
- -2.0 vs -0.4 NCT02681094
- -3.5 vs 1.8 NCT02471404
- -3.1 vs 1.8 NCT02471404
- -1.4 vs -2.0 NCT02243176
HbA1c below 7%
- Alogliptin
- 63.3% vs 30%+33.3 vs placeboNCT01289119
2 other results
- 55.1% vs 30% NCT01289119
- 61.7% vs 30% NCT01289119
- Saxagliptin
- 44.4% vs 16.6%+27.8 vs placeboNCT00121667
15 other results
- 41.1% vs 23.9% NCT00121641
- 43.5% vs 16.6% NCT00121667
- 37.9% vs 23.9% NCT00121641
- 22.1% vs 13.3% NCT00918879
- 45.8% vs 28.8% NCT00698932
- 37.1% vs 16.6% NCT00121667
- 35% vs 23.9% NCT00121641
- 37.5% vs 24.2% NCT00885378
- 21.3% vs 10% NCT03199053
- 36.7% vs 13.3% NCT01646320
- 21.4% vs 11.7% NCT02419612
- 44.3% vs 34.3% NCT02419612
- 37.3% vs 25.1% NCT02284893
- 37.2% vs 26.1% NCT00960076
- 38.3% vs 41.5% NCT02243176
Fasting plasma glucose, change
- Alogliptin
- -0.7 vs 0.3−1 vs placeboNCT00286429
351 other results
- -0.9 vs 0.6 NCT00286455
- -0.3 vs 0.7 NCT01023581
- -1.0 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.5 vs 0.1 NCT00286468
- -0.6 vs 0.5 NCT00286429
- -1.0 vs 0.4 NCT00286455
- -0.5 vs 0.5 NCT01023581
- -1.3 vs 0.4 NCT00328627
- -1.2 vs -0.4 NCT00286494
- -0.9 vs -0.0 NCT00286442
- -0.8 vs -0.0 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -1.0 vs 0.3 NCT00286455
- -0.4 vs 0.6 NCT01023581
- -1.3 vs 0.1 NCT00328627
- -1.3 vs -0.5 NCT00286494
- -0.8 vs 0.1 NCT00286442
- -0.7 vs -0.4 NCT00286468
- -0.2 vs -0.1 NCT00286429
- -1.1 vs 0.1 NCT00286455
- -0.5 vs 0.6 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.4 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -1.1 vs 0.1 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.5 vs -0.3 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -1.0 vs -0.2 NCT00286468
- -0.7 vs 0.3 NCT00286429
- -1.2 vs 0.2 NCT00286455
- -0.6 vs 0.4 NCT01023581
- -1.3 vs 0.2 NCT00328627
- -1.4 vs -0.2 NCT00286494
- -1 vs -0.0 NCT00286442
- -1.2 vs -0.2 NCT00286468
- -0.6 vs 0.1 NCT00286429
- -1.0 vs 0.2 NCT00286455
- -0.4 vs 0.3 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -1.2 vs -0.1 NCT00286468
- -0.6 vs 0.3 NCT00286429
- -0.8 vs 0.3 NCT00286455
- -0.2 vs 0.3 NCT01023581
- -1.0 vs 0.1 NCT00328627
- -1.0 vs -0.1 NCT00286494
- -0.7 vs -0.0 NCT00286442
- -1.1 vs 0.0 NCT00286468
- 0.1 vs 0.3 NCT00286429
- -0.6 vs 0.6 NCT00286455
- -0.5 vs 0.7 NCT01023581
- -0.7 vs 0.4 NCT00328627
- -1.1 vs -0.3 NCT00286494
- -1.0 vs 0 NCT00286442
- -0.3 vs 0.1 NCT00286468
- -0.2 vs 0.5 NCT00286429
- -0.7 vs 0.4 NCT00286455
- -0.7 vs 0.5 NCT01023581
- -0.5 vs 0.4 NCT00328627
- -1.2 vs -0.4 NCT00286494
- -1 vs -0.0 NCT00286442
- -0.5 vs -0.0 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.8 vs 0.3 NCT00286455
- -0.8 vs 0.6 NCT01023581
- -0.9 vs 0.1 NCT00328627
- -1.0 vs -0.5 NCT00286494
- -1.0 vs 0.1 NCT00286442
- -0.5 vs -0.4 NCT00286468
- -0.3 vs -0.1 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.8 vs 0.6 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -1.1 vs -0.6 NCT00286494
- -0.9 vs 0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.8 vs 0.3 NCT00286429
- -0.8 vs 0.1 NCT00286455
- -0.7 vs 0.4 NCT01023581
- -1.1 vs 0.3 NCT00328627
- -1.3 vs -0.3 NCT00286494
- -1.1 vs 0.0 NCT00286442
- -1.1 vs -0.2 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.9 vs 0.2 NCT00286455
- -0.9 vs 0.4 NCT01023581
- -1.1 vs 0.2 NCT00328627
- -1.3 vs -0.2 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -0.8 vs -0.2 NCT00286468
- -0.2 vs 0.1 NCT00286429
- -0.8 vs 0.2 NCT00286455
- -0.6 vs 0.3 NCT01023581
- -1.2 vs 0.3 NCT00328627
- -1.2 vs -0.1 NCT00286494
- -1.0 vs -0.0 NCT00286442
- -0.9 vs -0.1 NCT00286468
- -0.3 vs 0.3 NCT00286429
- -0.5 vs 0.3 NCT00286455
- -0.7 vs 0.3 NCT01023581
- -0.8 vs 0.1 NCT00328627
- -0.8 vs -0.1 NCT00286494
- -0.8 vs -0.0 NCT00286442
- -0.7 vs 0.0 NCT00286468
- -2.1 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -2.2 vs 0.4 NCT00328627
- -2.4 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -2.2 vs 0.1 NCT00328627
- -2.4 vs 0.1 NCT00328627
- -3.0 vs 0.1 NCT00328627
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -2.9 vs 0.2 NCT00328627
- -2.2 vs 0.3 NCT00328627
- -2.5 vs 0.3 NCT00328627
- -2.9 vs 0.3 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2 vs 0.2 NCT00328627
- -2.6 vs 0.2 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT00328627
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.4 vs 0.1 NCT00328627
- -1.8 vs 0.7 NCT01023581
- -2.5 vs 0.7 NCT01023581
- -2.3 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.9 vs 0.4 NCT00328627
- -1.9 vs 0.5 NCT01023581
- -2.5 vs 0.5 NCT01023581
- -2.4 vs 0.4 NCT00328627
- -2.3 vs 0.4 NCT00328627
- -2.6 vs 0.4 NCT00328627
- -2.0 vs 0.6 NCT01023581
- -2.6 vs 0.6 NCT01023581
- -2.3 vs 0.1 NCT00328627
- -2.3 vs 0.1 NCT00328627
- -2.7 vs 0.1 NCT00328627
- -1.8 vs 0.6 NCT01023581
- -2.5 vs 0.6 NCT01023581
- -2.4 vs 0.2 NCT00328627
- -2.4 vs 0.2 NCT00328627
- -2.7 vs 0.2 NCT00328627
- -1.8 vs 0.4 NCT01023581
- -2.4 vs 0.4 NCT01023581
- -2.4 vs 0.3 NCT00328627
- -2.3 vs 0.3 NCT00328627
- -2.4 vs 0.3 NCT00328627
- -2.1 vs 0.4 NCT01023581
- -2.5 vs 0.4 NCT01023581
- -2.0 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -2.1 vs 0.2 NCT00328627
- -1.9 vs 0.3 NCT01023581
- -2.4 vs 0.3 NCT01023581
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.7 vs 0.3 NCT00328627
- -1.8 vs 0.3 NCT01023581
- -2.0 vs 0.3 NCT01023581
- -1.2 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.3 vs 0.1 NCT00328627
- -1.2 vs -0.3 NCT01289119
- -1.2 vs -0.3 NCT01289119
- -0.9 vs 0.7 NCT00655863
- -0.9 vs 0.3 NCT00655863
- -1.1 vs -0.2 NCT00655863
- -2.1 vs 0.7 NCT00655863
- -2.1 vs 0.3 NCT00655863
- -2.2 vs -0.2 NCT00655863
- -1.1 vs -0.3 NCT01289119
- -1.1 vs -0.4 NCT01289119
- -1.3 vs -0.4 NCT01289119
- -1.2 vs -0.4 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.3 vs -0.3 NCT01289119
- -0.9 vs -0.3 NCT01289119
- -0.7 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -1.0 vs -0.3 NCT01289119
- -0.4 vs 0.1 NCT00856284
- -0.8 vs -0.2 NCT00432276
- -0.9 vs -0.3 NCT00432276
- -0.5 vs -0.0 NCT00856284
- -0.3 vs 0.1 NCT00856284
- -0.8 vs -0.3 NCT00432276
- -0.6 vs -0.2 NCT00856284
- -0.3 vs 0.3 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.6 vs -0.3 NCT00856284
- -0.9 vs -0.3 NCT00432276
- -0.6 vs -0.4 NCT00856284
- -1 vs -0.3 NCT00432276
- -0.2 vs 0.3 NCT00856284
- -0.6 vs -0.5 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -0.6 vs -0.5 NCT00856284
- -1.1 vs -0.3 NCT00432276
- -0.6 vs -0.6 NCT00856284
- -1.0 vs -0.1 NCT00432276
- -0.6 vs -0.4 NCT00856284
- -0.9 vs -0.0 NCT00432276
- -0.2 vs 0.3 NCT00856284
- -0.3 vs 0.1 NCT00856284
- -0.4 vs -0.0 NCT00856284
- -0.2 vs 0.1 NCT00856284
- -0.4 vs -0.2 NCT00856284
- -0.2 vs 0.3 NCT00856284
- -0.4 vs -0.3 NCT00856284
- -0.5 vs -0.4 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -0.6 vs -0.5 NCT00856284
- -0.5 vs -0.5 NCT00856284
- -0.6 vs -0.6 NCT00856284
- -0.6 vs -0.4 NCT00856284
- -0.1 vs 0.3 NCT00856284
- -1.4 vs -2.1 NCT00395512
- -1.6 vs -2.3 NCT00395512
- -1.5 vs -2.3 NCT00395512
- -1.6 vs -2.4 NCT00395512
- -1.6 vs -2.1 NCT00395512
- -1.5 vs -1.8 NCT00395512
- -0.9 vs -0.8 NCT00395512
- -0.8 vs -0.4 NCT00395512
- -1.1 vs -0.3 NCT01263483
- -1.1 vs -0.1 NCT01263483
- -0.9 vs -0.0 NCT01263483
- -0.9 vs -0.2 NCT01263483
- -2.8 vs -2.1 NCT00395512
- -3 vs -2.3 NCT00395512
- -2.9 vs -2.3 NCT00395512
- -2.9 vs -2.4 NCT00395512
- -0.9 vs 0.3 NCT01318083
- -1.1 vs -0.1 NCT01318070
- -1.0 vs -0.3 NCT01263483
- -2.8 vs -2.1 NCT00395512
- -1.0 vs 0.3 NCT01318083
- -1.2 vs -0.2 NCT01318070
- -1.2 vs -0.1 NCT01263483
- -2.3 vs -1.8 NCT00395512
- -1.3 vs 0.1 NCT01318083
- -1.0 vs -0.2 NCT01318070
- -1.3 vs -0.0 NCT01263483
- -1.9 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -1.0 vs -0.2 NCT01263483
- -1.5 vs -0.4 NCT00395512
- -2.7 vs -2.1 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -2.6 vs -2.3 NCT00395512
- -2.7 vs -2.4 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.8 vs -0.1 NCT01318070
- -2.7 vs -2.1 NCT00395512
- -1.2 vs 0.3 NCT01318083
- -0.9 vs -0.2 NCT01318070
- -2.2 vs -1.8 NCT00395512
- -1.2 vs 0.1 NCT01318083
- -0.8 vs -0.2 NCT01318070
- -1.7 vs -0.8 NCT00395512
- -1.0 vs 0.0 NCT01318083
- -0.7 vs -0.2 NCT01318070
- -1.3 vs -0.4 NCT00395512
- -1.5 vs 0.5 NCT00755846
- -1.0 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT01263470
- -1.4 vs 0.3 NCT00755846
- -1.1 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -0.3 vs 0.5 NCT00755846
- -0.8 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT01263470
- -0.6 vs 0.3 NCT00755846
- -1.2 vs 0.5 NCT01263470
- -0.9 vs 0.1 NCT01263470
- -1.2 vs 0.5 NCT00755846
- -1.4 vs 0.3 NCT00755846
- -0.9 vs 0.5 NCT00755846
- -1.3 vs 0.3 NCT01263470
- -1.3 vs 0.3 NCT01263470
- -1.0 vs 0.3 NCT00755846
- -1.3 vs 0.5 NCT01263470
- -1.2 vs 0.1 NCT01263470
- -0.4 vs 0.5 NCT00755846
- -0.5 vs 0.3 NCT01263470
- -0.7 vs 0.3 NCT01263470
- -0.4 vs 0.3 NCT00755846
- -0.9 vs 0.5 NCT01263470
- -0.8 vs 0.1 NCT01263470
- -1.2 vs -0.7 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.4 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.9 vs -0.2 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -1.1 vs -0.7 NCT01263496
- -1.1 vs -0.8 NCT01263496
- -1.0 vs -0.8 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.7 vs -0.4 NCT01263496
- -0.7 vs -0.5 NCT01263496
- -0.8 vs -0.3 NCT01263496
- -0.9 vs -0.4 NCT01263496
- -0.8 vs -0.2 NCT01263496
- -0.9 vs -0.5 NCT01263496
- -1.4 vs -0.7 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.4 vs -0.8 NCT01263496
- -1.3 vs -0.8 NCT01263496
- -1.2 vs -0.5 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.1 vs -0.4 NCT01263496
- -1.1 vs -0.5 NCT01263496
- -1.1 vs -0.3 NCT01263496
- -1.0 vs -0.4 NCT01263496
- -1.3 vs -0.2 NCT01263496
- -1.5 vs -0.5 NCT01263496
- -0.8 vs -0.7 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.9 vs -0.8 NCT01263496
- -0.8 vs -0.8 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.8 vs -0.5 NCT01263496
- -0.5 vs -0.4 NCT01263496
- -0.6 vs -0.5 NCT01263496
- -0.6 vs -0.3 NCT01263496
- -0.6 vs -0.4 NCT01263496
- -0.7 vs -0.2 NCT01263496
- -0.6 vs -0.5 NCT01263496
- Saxagliptin
- -0.6 vs -0.3−0.2 vs placeboNCT00757588
11 other results
- -0.5 vs -0.3 NCT01619059
- 0.1 vs 0.2 NCT03199053
- -1.8 vs -0.3 NCT01646320
- -0.3 vs 0.1 NCT01128153
- -1.8 vs -0.6 NCT02284893
- -2.4 vs -1.0 NCT03199053
- -0.6 vs -1.0 NCT03199053
- -1.6 vs -1.5 NCT02471404
- -0.7 vs -1.3 NCT01006603
- -2.1 vs -1.5 NCT02471404
- -1.0 vs -1.0 NCT02243176
3-point MACE (% with event)
- Alogliptin
- 11.3% vs 11.8%−0.5 vs placeboNCT00968708
- Saxagliptin
- 7.4% vs 7.4%±0 vs placeboNCT01107886
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
9 other shared endpoints and safety
Coverage. Alogliptin: 13 of 13 rows · Saxagliptin: 13 of 13 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Alogliptin Rows use multiple source trials | Saxagliptin Rows use multiple source trials |
|---|---|---|
| Fasting Plasma Glucose absolute change · mmol/L No placebo or comparator arm | -0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,b,c,d NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted show 3 more doses-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted -0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted -0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted | -0.55 mmol/L @ 24wkb,c,d NCT01608724 · Phase 4 · registry result, not featured evidence 1 other source trial-0.62 mmol/L @ 24wk* NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -11.23 mg/dL as posted |
| Glycemic Rescue responder rate · % of participants | 12.8% (n=125) vs 32.8% (n=125) placebo25 mga,c,e NCT00328627 · Phase 3 · registry result, not featured evidence show 7 more doses14.5% (n=124) vs 32.8% (n=125) placebo12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 3.9% (n=129) vs 32.8% (n=125) placebo25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.9% (n=123) vs 32.8% (n=125) placebo25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.6% (n=125) vs 32.8% (n=125) placebo25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.7% (n=129) vs 32.8% (n=125) placebo12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.8% (n=126) vs 32.8% (n=125) placebo12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 2.4% (n=127) vs 32.8% (n=125) placebo12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination | 37% (n=227) vs 55.6% (n=216) Glimepiride @ 156wkdapagliflozin 10 mg, saxagliptin 5 mgc,e NCT02419612 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.7% (n=145) @ 24wk25 mg QD and 1-6 mg QD or BIDa,f,c NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination show 3 more doses-0.78% (n=134) @ 24wk25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination -0.59% (n=137) @ 24wk12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination -0.68% (n=135) @ 24wk12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination | -0.64% (n=229) @ 24wkf,c NCT02104804 · Phase 3 · registry result, not featured evidence · combination |
| HbA1c 7.0 or Less event count · % of participants | 7.8% (n=129) vs 0.8% (n=129) placebo @ 26wk*25 mg QDa,c,d,g NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 10 participants as posted show 1 more dose8.4% (n=131) vs 0.8% (n=129) placebo @ 26wk*12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted | 30.7% (n=127) vs 9.4% (n=127) placebo @ 24wk*c,d,g NCT01128153 · Phase 3 · registry result, not featured evidence · converted to % from 39 Participants as posted |
| HbA1c Less Than 7% event count · % of participants | 44.4% (n=207) vs 18.3% (n=104) placebo @ 26wk*25 mg QDa,c,d,g NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 92 participants as posted show 1 more dose51.6% (n=213) vs 18.3% (n=104) placebo @ 26wk*12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 110 participants as posted | 42.8% (n=290) vs 21.8% (n=289) Dapagliflozin + Metformin @ 24wk*c,d,g NCT02681094 · Phase 3 · registry result, not featured evidence · add on · converted to % from 124 Participants as posted |
| HbA1c Less Than or Equal to 6.5 responder rate · % of participants | 24.1% (n=878) vs 19% (n=869) Glipizide @ 104wk25 mga,c,h NCT00856284 · Phase 3 · registry result, not featured evidence · combination show 1 more dose23.5% (n=873) vs 19% (n=869) Glipizide @ 104wk12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination | 24.6% (n=74) vs 10.7% (n=84) placebo @ 12wk2.5 mgc,h NCT00885378 · Phase 3 · registry result, not featured evidence · combination |
| PPG 2h Change mg/dL absolute change · mmol/L | 3.08 vs 3.14 Voglibose mmol/L @ 24wk*25 mg QDa,i,c,d NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted show 7 more doses3.35 vs 2.92 Voglibose mmol/L*25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 60.4 mg/dL as posted 3.08 vs 3.14 Voglibose mmol/L @ 24wk*12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted 3.54 vs 2.92 Voglibose mmol/L*12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 63.8 mg/dL as posted 3.1 vs 3.14 Voglibose mmol/L @ 24wk*50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.9 mg/dL as posted 2.92 vs 2.92 Voglibose mmol/L*50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 52.6 mg/dL as posted 3.57 vs 3.14 Voglibose mmol/L @ 24wk*6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 64.3 mg/dL as posted 3.61 vs 2.92 Voglibose mmol/L*6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65 mg/dL as posted | -4.08 vs -2.11 placebo mmol/L @ 24wk*i,c,d NCT01646320 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -73.5 mg/dL as posted 2 other source trials-2.06 vs -1.74 placebo mmol/L @ 24wk*5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -37.1 mg/dL as posted -1.51 vs -0.23 placebo mmol/L @ 24wk*5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -27.2 mg/dL as posted |
| PPG 2h Change mg/dL absolute change · mmol/L No placebo or comparator arm | 2.06 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,f,c NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 37.1 mg/dL as posted show 3 more doses2.19 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.4 mg/dL as posted 2.11 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 38 mg/dL as posted 2.2 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from 39.6 mg/dL as posted | -1.68 mmol/L @ 24wk*f,c NCT02104804 · Phase 3 · registry result, not featured evidence · combination · converted to mmol/L from -30.28 mg/dL as posted |
| PPG AUC Change Mgmin dL absolute change · mg No placebo or comparator arm | -70.4 mg @ 24wkAlogliptin 25 mg QD and Voglibose 0.2 mg TIDa,f,c NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination show 3 more doses-82.2 mgAlogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination -69 mg @ 24wkAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination -77.5 mgAlogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination | -4702.2 mg @ 24wkf,c NCT02104804 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | 40.3%25 mg QDj NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results36.6%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.3%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 21.1%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 20%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 11% NCT00968708 · Phase 3 14.9% NCT01456130 · Phase 3 · registry result, not featured evidence 44.3%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 46.4%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.8%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 6.1%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 36.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 38.8%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 20.5%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 37.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 17.1%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 0%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 4.5%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 21.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 24.2%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 15.4%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.1%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.3%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 11.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 10.8%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 13.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 23.2%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 17.1%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 23.2%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 19.6%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 22.3%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 21.4%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 17.4%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 25.3%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 24.6%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1.9%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 5.7%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 2.6%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 6.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 3.8%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 4.8%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 3.8%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 6.3%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 28.9%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 27.3%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 31.1%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 38.6%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 12.5%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 22.7%10 mgk NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results25.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 22.9%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 29.6%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 35.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 28.4%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 0% NCT02024477 · Phase 4 · registry result, not featured evidence 10.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 4.5%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 5.7% NCT02243176 · Phase 4 · registry result, not featured evidence 17.1% NCT01608724 · Phase 4 · registry result, not featured evidence 2.4% NCT01107886 · Phase 4 · registry result, not featured evidence 19.7%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 19% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 5.7%Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 7.5%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 8.6% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 8.2% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 25% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 6.8%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.5%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.2%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 12.4% NCT01128153 · Phase 3 · registry result, not featured evidence 5.8% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 61.4% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5.6%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 4.3%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 11.8%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 50.6% NCT00614939 · Phase 3 · registry result, not featured evidence 10.8%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 15%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 7.7%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 10.2%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 4.7%25 mg QDj NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results0.8%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.3%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 5.6% NCT00968708 · Phase 3 6% NCT01456130 · Phase 3 · registry result, not featured evidence 8.4%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 6.8%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 1.1%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 2%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 0%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 6.2%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 7.4%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 3.6%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 6.2%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 4.5%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination —25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence —25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 1.6%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 1.5%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.1%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.8%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.8%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 3.7%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3.7%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 3%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 4.1%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 3.3%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 3%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence —25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination —12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 3.8%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination —Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 3.8%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination —25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence —6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 1.2%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 4.4%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 6.8%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —25 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence —12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 2.8%10 mgk NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results3.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.1%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02024477 · Phase 4 · registry result, not featured evidence 2.2%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 0.3%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT02243176 · Phase 4 · registry result, not featured evidence 2% NCT01608724 · Phase 4 · registry result, not featured evidence — NCT01107886 · Phase 4 · registry result, not featured evidence 4.2%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 1.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 0.4%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence — NCT02551874 · Phase 3 · registry result, not featured evidence · combination 3.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 0.4% NCT02284893 · Phase 3 · registry result, not featured evidence · combination — NCT01204775 · Phase 3 · registry result, not featured evidence — NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 1.7%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 1.9%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 0.8% NCT01128153 · Phase 3 · registry result, not featured evidence 0.7% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 2.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00918879 · Phase 3 · registry result, not featured evidence —5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 5.9% NCT00614939 · Phase 3 · registry result, not featured evidence —2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 0%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 1.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | 5.4%25 mg QDj NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results6.1%12.5 mg QD NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8%25 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 3.8%12.5 mg QD NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 2.7%25 mg NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 33.6% NCT00968708 · Phase 3 9% NCT01456130 · Phase 3 · registry result, not featured evidence 11%25 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 9.9%12.5 mg NCT00856284 · Phase 3 · registry result, not featured evidence · combination 2.2%Alogliptin Monotherapy NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy 0%Metformin + Alogliptin Add-on Ther NCT01289119 · Phase 3 · registry result, not featured evidence · combination 1.6%Pioglitazone + Alogliptin Add-on T NCT01289119 · Phase 3 · registry result, not featured evidence · combination 16.3%25 mg NCT00306384 · Phase 3 · registry result, not featured evidence 16.7%12.5 mg NCT00306384 · Phase 3 · registry result, not featured evidence 0.9%25 mg QD NCT01023581 · Phase 3 · registry result, not featured evidence 3.6%12.5 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence 1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 1.9%alogliptin 12.5 mg BID + metformin 500 mg BID NCT01023581 · Phase 3 · registry result, not featured evidence · combination 8%25 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence 13.6%25 mg QD + 30 mg QD NCT00655863 · Phase 3 · registry result, not featured evidence · combination 5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin NCT00432276 · Phase 3 · registry result, not featured evidence · combination 4.7%25 mg NCT00328627 · Phase 3 · registry result, not featured evidence 3.9%12.5 mg NCT00328627 · Phase 3 · registry result, not featured evidence 0.8%25 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 4.6%25 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 3.8%25 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 15 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 2.3%12.5 mg + 30 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 1.5%12.5 mg + 45 mg NCT00328627 · Phase 3 · registry result, not featured evidence · combination 0.6%25 mg NCT00395512 · Phase 3 · registry result, not featured evidence 4.9%25 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 0.6%12.5 mg + 30 mg NCT00395512 · Phase 3 · registry result, not featured evidence · combination 6.5%25 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 2.5%12.5 mg QD NCT00286494 · Phase 3 · registry result, not featured evidence 3.9%25 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 2.8%12.5 mg QD NCT00286442 · Phase 3 · registry result, not featured evidence 5.6%25 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 5.4%12.5 mg QD NCT00286468 · Phase 3 · registry result, not featured evidence 2%25 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 3.4%25 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 10.7%12.5 mg QD and 1-6 mg QD or BID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 4.9%12.5 mg QD and 500 mg BID or 750 mg TID NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 1%25 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 2.9%12.5 mg QD NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination 1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 0%12.5 mg QD NCT01263483 · Phase 2/3 · registry result, not featured evidence 1.3%25 mg QD + 0.2 mg TID NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 8.2%25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 7.9%12.5 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 5.2%50 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 2.1%6.25 mg QD NCT01263496 · Phase 2 · registry result, not featured evidence 1.3%25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.4%12.5 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%50 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.5%6.25 mg QD NCT01263470 · Phase 2 · registry result, not featured evidence 2.2%25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%12.5 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%100 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%50 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 2.4%6.25 mg QD NCT00755846 · Phase 2 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%25 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 0%12.5 mg NCT00957268 · Phase 1 · registry result, not featured evidence 10%Roflumilast + Alogliptin NCT01664624 · Phase 1 · registry result, not featured evidence · combination 0%Roflumilast Alone NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 12.2%10 mgk NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results14.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 17%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.8%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.8% NCT02024477 · Phase 4 · registry result, not featured evidence 12.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 7.1%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT02243176 · Phase 4 · registry result, not featured evidence 1.8% NCT01608724 · Phase 4 · registry result, not featured evidence 25.5% NCT01107886 · Phase 4 · registry result, not featured evidence 11.4%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 4.1% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 3.8%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.3%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 1.6%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 4.9%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 12.8%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 6.2% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 3.9% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 0% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence 5.1%5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination —Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination 4.4%DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination —Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 4.6%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination 1.1% NCT01606007 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01128153 · Phase 3 · registry result, not featured evidence 0% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 2.2%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 8.2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 27.1% NCT00614939 · Phase 3 · registry result, not featured evidence 1.4%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 5%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 25 mg QDj urinary tract infection 7% (placebo 7.8%) diarrhoea 6.2% (placebo 5.4%) nasopharyngitis 6.2% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 69 more results12.5 mg QD arthralgia 6.9% (placebo 2.3%) urinary tract infection 6.1% (placebo 7.8%) headache 5.3% (placebo 4.7%) NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 25 mg QD nasopharyngitis 7.6% (placebo 7.8%) headache 6.8% (placebo 4.7%) upper respiratory tract infection 4.5% (placebo 9.4%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 12.5 mg QD nasopharyngitis 9% (placebo 7.8%) headache 7.5% (placebo 4.7%) back pain 5.3% (placebo 4.7%) NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 25 mg headache 18.7% (placebo 10.5%) hyperglycaemia 12% (placebo 11.8%) diarrhoea 9.3% (placebo 9.2%) NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3 renal impairment 7.5% (placebo 6.5%) hypertension 7.1% (placebo 7.4%) hypoglycaemia 6.2% (placebo 5.9%) NCT00968708 · Phase 3 nasopharyngitis 35.8% upper respiratory tract inflammation 11.9% arthralgia 7.5% NCT01456130 · Phase 3 · registry result, not featured evidence 25 mg upper respiratory tract infection 10.3% hypertension 7.6% nasopharyngitis 7.6% NCT00856284 · Phase 3 · registry result, not featured evidence · combination 12.5 mg upper respiratory tract infection 9.6% nasopharyngitis 8.9% diarrhoea 6.9% NCT00856284 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 6.5% (placebo 1.1%) upper respiratory tract infection 5.4% (placebo 3.3%) blood triglycerides increased 2.2% (placebo 1.1%) NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy upper respiratory tract infection 3% (placebo 3.3%) blood triglycerides increased 2% (placebo 1.1%) urinary tract infection 2% (placebo 6.5%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination hyperlipidaemia 21.3% (placebo 1.1%) urinary tract infection 6.6% (placebo 6.5%) upper respiratory tract infection 3.3% (placebo 3.3%) NCT01289119 · Phase 3 · registry result, not featured evidence · combination 25 mg hypertension 14.5% urinary tract infection 11.7% nasopharyngitis 11.6% NCT00306384 · Phase 3 · registry result, not featured evidence 12.5 mg hypertension 14.8% upper respiratory tract infection 11.6% urinary tract infection 11.1% NCT00306384 · Phase 3 · registry result, not featured evidence 25 mg QD hyperglycaemia 17% (placebo 26.4%) nasopharyngitis 6.3% (placebo 1.9%) headache 5.4% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence 12.5 mg BID hyperglycaemia 11.8% (placebo 26.4%) headache 4.5% (placebo 2.8%) creatinine renal clearance decreased 3.6% (placebo 3.8%) NCT01023581 · Phase 3 · registry result, not featured evidence alogliptin 12.5 mg BID + metformin 1000 mg BID creatinine renal clearance decreased 7.9% (placebo 3.8%) diarrhoea 7% (placebo 2.8%) dyspepsia 7% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination alogliptin 12.5 mg BID + metformin 500 mg BID hyperglycaemia 7.5% (placebo 26.4%) upper respiratory tract infection 7.5% (placebo 2.8%) headache 6.6% (placebo 2.8%) NCT01023581 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 20% (placebo 4.2%) anaemia 12% (placebo 4.2%) constipation 8% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence 25 mg QD + 30 mg QD hypoglycaemia 13.6% (placebo 0%) nasopharyngitis 13.6% (placebo 4.2%) constipation 9.1% (placebo 4.2%) NCT00655863 · Phase 3 · registry result, not featured evidence · combination Alogliptin 25 mg; Pioglitazone 30 mg; Metformin upper respiratory tract infection 7.2% nasopharyngitis 6.9% hypertension 5.9% NCT00432276 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 7% (placebo 4.7%) upper respiratory tract infection 6.2% (placebo 3.9%) abdominal pain upper 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence 12.5 mg hypertriglyceridaemia 5.5% (placebo 2.3%) hypertension 4.7% (placebo 3.1%) urinary tract infection 4.7% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence 25 mg + 15 mg influenza 6.2% (placebo 2.3%) nasopharyngitis 6.2% (placebo 3.9%) oedema peripheral 5.4% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 30 mg nasopharyngitis 6.9% (placebo 3.9%) back pain 6.2% (placebo 3.9%) influenza 6.2% (placebo 2.3%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg + 45 mg diarrhoea 5.4% (placebo 8.5%) headache 4.6% (placebo 4.7%) oedema peripheral 4.6% (placebo 1.6%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 15 mg hypertension 6.9% (placebo 3.1%) nasopharyngitis 6.2% (placebo 3.9%) dizziness 5.4% (placebo 3.1%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg dizziness 3.8% (placebo 3.1%) nasopharyngitis 3.8% (placebo 3.9%) upper respiratory tract infection 3.8% (placebo 3.9%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 45 mg back pain 9.2% (placebo 3.9%) dizziness 4.6% (placebo 3.1%) headache 4.6% (placebo 4.7%) NCT00328627 · Phase 3 · registry result, not featured evidence · combination 25 mg headache 6.7% urinary tract infection 3% oedema peripheral 1.2% NCT00395512 · Phase 3 · registry result, not featured evidence 25 mg + 30 mg headache 12.2% back pain 6.1% urinary tract infection 5.5% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 12.5 mg + 30 mg headache 8.6% urinary tract infection 3.7% back pain 1.8% NCT00395512 · Phase 3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 7% (placebo 6.2%) influenza 5.5% (placebo 4.1%) oedema peripheral 5.5% (placebo 7.2%) NCT00286494 · Phase 3 · registry result, not featured evidence 12.5 mg QD oedema peripheral 6.1% (placebo 7.2%) upper respiratory tract infection 5.6% (placebo 5.2%) nausea 4.5% (placebo 2.1%) NCT00286494 · Phase 3 · registry result, not featured evidence 25 mg QD diarrhoea 3.4% (placebo 5.8%) nasopharyngitis 3.4% (placebo 5.8%) bronchitis 2.9% (placebo 1.9%) NCT00286442 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 6.6% (placebo 3.8%) nasopharyngitis 5.6% (placebo 5.8%) upper respiratory tract infection 4.7% (placebo 6.7%) NCT00286442 · Phase 3 · registry result, not featured evidence 25 mg QD headache 5.6% (placebo 3%) hypertension 5.6% (placebo 2%) urinary tract infection 5.1% (placebo 3%) NCT00286468 · Phase 3 · registry result, not featured evidence 12.5 mg QD urinary tract infection 4.4% (placebo 3%) diarrhoea 3.9% (placebo 0%) hypertriglyceridaemia 3.9% (placebo 2%) NCT00286468 · Phase 3 · registry result, not featured evidence 25 mg QD and 1-6 mg QD or BID nasopharyngitis 37.5% upper respiratory tract inflammation 10.5% fall 7.9% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 36.6% diabetic retinopathy 6.9% constipation 5.5% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 1-6 mg QD or BID nasopharyngitis 30.7% upper respiratory tract inflammation 6.7% back pain 5.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD and 500 mg BID or 750 mg TID nasopharyngitis 31% back pain 6.3% headache 6.3% NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 19.2% upper respiratory tract inflammation 11.5% back pain 3.8% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 19% gastroenteritis 3.8% upper respiratory tract inflammation 1.9% NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 25 mg QD and Voglibose 0.2 mg TID nasopharyngitis 28.6% back pain 5.7% arthralgia 4.8% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID nasopharyngitis 35.2% upper respiratory tract inflammation 11.1% back pain 7.4% NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 11.5% blood creatine phosphokinase increased 3.5% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD nasopharyngitis 4.5% blood creatine phosphokinase increased 0% dental caries 0% NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination 12.5 mg QD nasopharyngitis 22.4% eczema 1.3% NCT01263483 · Phase 2/3 · registry result, not featured evidence 25 mg QD + 0.2 mg TID nasopharyngitis 16.5% eczema 0% NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination 25 mg QD nasopharyngitis 33% headache 7.2% upper respiratory tract inflammation 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 28.7% bronchitis 5.9% back pain 5% NCT01263496 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 35.1% blood creatine phosphokinase increased 8.2% back pain 7.2% NCT01263496 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 30.2% upper respiratory tract inflammation 8.3% back pain 7.3% NCT01263496 · Phase 2 · registry result, not featured evidence 25 mg QD nasopharyngitis 12.5% (placebo 6.7%) headache 6.3% (placebo 5.3%) abdominal distension 3.8% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 12.5 mg QD nasopharyngitis 8.3% (placebo 6.7%) flatulence 4.8% (placebo 2.7%) urticaria 3.6% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 50 mg QD nasopharyngitis 10.1% (placebo 6.7%) blood creatine phosphokinase increased 5.1% (placebo 2.7%) abdominal distension 2.5% (placebo 0%) NCT01263470 · Phase 2 · registry result, not featured evidence 6.25 mg QD nasopharyngitis 6.3% (placebo 6.7%) bronchitis 3.8% (placebo 1.3%) flatulence 2.5% (placebo 2.7%) NCT01263470 · Phase 2 · registry result, not featured evidence 25 mg QD headache 8.9% (placebo 7.3%) abdominal pain upper 6.7% (placebo 0%) dizziness 6.7% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 12.5 mg QD rash 9.1% (placebo 2.4%) abdominal pain 4.5% (placebo 0%) arthralgia 4.5% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 100 mg QD nausea 11.4% (placebo 0%) headache 9.1% (placebo 7.3%) urinary tract infection 9.1% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 50 mg QD diarrhoea 7% (placebo 7.3%) headache 7% (placebo 7.3%) urinary tract infection 7% (placebo 9.8%) NCT00755846 · Phase 2 · registry result, not featured evidence 6.25 mg QD urinary tract infection 7.1% (placebo 9.8%) abdominal pain upper 4.8% (placebo 0%) dizziness 4.8% (placebo 0%) NCT00755846 · Phase 2 · registry result, not featured evidence 25 mg rash papular 25% abdominal pain 0% blood creatine phosphokinase increased 0% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg blood creatine phosphokinase increased 14.3% haematocrit decreased 14.3% haemoglobin decreased 14.3% NCT00957268 · Phase 1 · registry result, not featured evidence 25 mg headache 18.2% fatigue 9.1% nausea 9.1% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg diarrhoea 20% neutrophil count decreased 20% pyrexia 20% NCT00957268 · Phase 1 · registry result, not featured evidence 12.5 mg abdominal pain 25% gastritis 12.5% headache 12.5% NCT00957268 · Phase 1 · registry result, not featured evidence headache 30% nausea 20% constipation 10% NCT01664624 · Phase 1 · registry result, not featured evidence · combination nausea 50% diarrhoea 40% vomiting 30% NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy | 10 mgk influenza 15.5% (placebo 15.1%) nasopharyngitis 15.5% (placebo 14%) headache 13.3% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results5 mg influenza 16.2% (placebo 15.1%) nasopharyngitis 14.7% (placebo 14%) arthralgia 10.5% (placebo 6.7%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 15.1% (placebo 12.8%) nasopharyngitis 14.6% (placebo 14%) headache 14.1% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg arthralgia 16.3% (placebo 7.4%) headache 16.3% (placebo 16.8%) influenza 15.3% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg upper respiratory tract infection 15.1% (placebo 15.8%) urinary tract infection 13.2% (placebo 8.4%) headache 12.3% (placebo 16.8%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 13.7% (placebo 8.4%) upper respiratory tract infection 11.8% (placebo 15.8%) influenza 10.8% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5mg and 10mg nasopharyngitis 9.9% NCT02471404 · Phase 4 · registry result, not featured evidence · combination hyperlipidaemia 6.2% hyperlipidaemia 3.7% abdominal distension 1.2% NCT02243176 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 2.7% dizziness 2.6% NCT01608724 · Phase 4 · registry result, not featured evidence diabetes mellitus 6.5% (placebo 8.1%) dizziness 4.5% (placebo 4.2%) hypertension 4.2% (placebo 3.9%) NCT01107886 · Phase 4 · registry result, not featured evidence 5 mg nasopharyngitis 6.4% arthralgia 4.7% diarrhoea 4.2% NCT01006603 · Phase 4 · registry result, not featured evidence hypoglycaemia 6.8% diarrhoea 6.1% nasopharyngitis 5.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 5 mg toothache 7.7% (placebo 0%) acne 3.8% (placebo 0%) animal bite 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg aphthous ulcer 3.8% (placebo 0%) back pain 3.8% (placebo 2.6%) colitis 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 15.4% (placebo 2.6%) asthma 7.7% (placebo 0%) covid-19 7.7% (placebo 2.6%) NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.5 mg vitamin d deficiency 4.5% (placebo 6.6%) nausea 3.4% (placebo 0%) urinary tract infection 3.4% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg influenza 4.9% (placebo 2.6%) bronchitis 1.6% (placebo 0%) chronic sinusitis 1.6% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg covid-19 6.6% (placebo 2.6%) upper respiratory tract infection 6.6% (placebo 2.6%) urinary tract infection 4.9% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence dapagliflozin 10 mg, saxagliptin 5 mg urinary tract infection 13.7% upper respiratory tract infection 10.1% headache 7.9% NCT02419612 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.7% upper respiratory tract infection 5.2% headache 3.7% NCT02551874 · Phase 3 · registry result, not featured evidence · combination glomerular filtration rate decreased 4.1% pollakiuria 2.4% urinary tract infection 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on nasopharyngitis 7.8% headache 5.6% urinary tract infection 4.3% NCT02284893 · Phase 3 · registry result, not featured evidence · combination oropharyngeal pain 50% (placebo 25%) acne 25% (placebo 0%) cough 25% (placebo 25%) NCT01204775 · Phase 3 · registry result, not featured evidence headache 50% (placebo 0%) abdominal pain upper 25% (placebo 0%) back pain 25% (placebo 0%) NCT01434186 · Phase 3 · registry result, not featured evidence 5 mg QD hypoglycaemia 21.8% (placebo 23.8%) upper respiratory tract infection 2.6% (placebo 4.3%) urinary tract infection 2.6% (placebo 0.9%) NCT02104804 · Phase 3 · registry result, not featured evidence · combination urinary tract infection 9.4% (placebo 10%) influenza 7.5% (placebo 7.5%) headache 6.9% (placebo 8.1%) NCT01646320 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.2% (placebo 6.8%) headache 5.9% (placebo 7.4%) nasopharyngitis 5.9% (placebo 4.9%) NCT01619059 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.2% (placebo 9.4%) diarrhoea 5.4% (placebo 3.9%) hypertension 5.4% (placebo 1.6%) NCT01128153 · Phase 3 · registry result, not featured evidence diarrhoea 5.8% urinary tract infection 5.1% nasopharyngitis 4.3% NCT00960076 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% diarrhoea 5.8% upper respiratory tract infection 5.8% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 8.4% (placebo 9.4%) NCT00918879 · Phase 3 · registry result, not featured evidence 5 mg + Metformin XR 1500 mg cough 6.5% NCT00918138 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.6% (placebo 7.9%) nasopharyngitis 6.3% (placebo 6.6%) upper respiratory tract infection 6.3% (placebo 7.3%) NCT00757588 · Phase 3 · registry result, not featured evidence · combination hypoglycaemia 28.2% (placebo 29.4%) anaemia 5.9% (placebo 8.2%) hypertension 5.9% (placebo 5.9%) NCT00614939 · Phase 3 · registry result, not featured evidence 5 mg headache 25% (placebo 18.8%) muscle spasms 25% (placebo 0%) infusion site pain 20% (placebo 12.5%) NCT00374907 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.3% (placebo 7.7%) NCT00698932 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.7% (placebo 4.5%) NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 4 versus Phase 2/3.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fTrial phases differ: Phase 3 versus Phase 2/3.
- gAssessment timepoints differ: 24 weeks versus 26 weeks.
- hAssessment timepoints differ: 12 weeks versus 104 weeks.
- iTrial phases differ: Phase 3 versus Phase 2.
- jPopulation comparability has not been reviewed for 65 of these studies.
- kPopulation comparability has not been reviewed for 38 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Alogliptin
show 5 more results
show 7 more results
show 7 more results
show 9 more results
show 9 more results
show 9 more results
show 9 more results
show 18 more results
show 2 more results
+ 49 further endpoints in the CSV export.
Saxagliptin
show 8 more results
show 6 more results
show 3 more results
show 4 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
+ 36 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Saxagliptin's landscape